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A B S T R A C T
Inulin is a soluble dietary fibre, also classified as a prebiotic, extracted from chicory roots. The present study
aimed to determine the effect of consumption of native chicory inulin on the stool frequency of middle-aged to
older adults (40–75 years old) with uncomfortably but not clinically relevant low stool frequency, specified as
two to four days without bowel movements per week. Two randomised, double blind, placebo-controlled
crossover trials were conducted using similar protocols in differing populations. Trial A was conducted in
Amsterdam, The Netherlands and subsequently Trial B was conducted in Newcastle, United Kingdom. Both trials
involved supplementation for 5 weeks with 10 g per day of inulin or placebo, a washout period of 2 weeks, and
then crossed over to receive the other treatment. In Trial B, faecal gut microbiota composition was assessed using
16S rRNA gene sequencing. In Trial A, which 10 volunteers completed, the stool frequency was significantly
increased to an average 4.9 ± 0.23 (SEM) times per week during inulin periods versus 3.6 ± 0.25 in the
periods with placebo (p=0.01). In contrast, in Trial B which 20 volunteers completed, there was no significant
effect of the inulin on stool frequency (7.5 ± 2.1 times per week with inulin, 8.1 ± 3.0 with placebo,
p=0.35). However, many subjects in Trial B had a stool frequency> 5 per week also for the placebo period, in
breach of the inclusion criteria. Combining the data of 16 low stool frequency subjects from Trials A and B
showed a significant effect of inulin to increase stool frequency from 4.1 to 5.0 per week (p=0.032). Regarding
secondary outcomes, stool consistency was significantly softer with inulin treatment compared to placebo
periods, it increased 0.29 on the Bristol stool scale (p=0.008) when data from all subjects of Trials A and B were
combined. No other differences in bowel habit parameters due to inulin consumption were significant. None of
the differences in specific bacterial abundance, alpha or beta diversity were significant, however the trends were
in directions consistent with published studies on other types of inulin. We conclude that 10 g per day of native
chicory inulin can increase stool frequency in subjects with low stool frequency.
1. Introduction
Constipation is a gastrointestinal tract (GIT) symptom that is char-
acterised by irregular, difficult and/or painful stool expulsion and hard,
dry stool consistency (Mccrea et al., 2009), and can cause additional
GIT symptoms such as distention, abdominal pain and poor appetite,
amongst others (Lembo & Camilleri, 2003). The prevalence of con-
stipation is difficult to determine as most people do not seek medical
treatment, however, it is estimated to cause recognised discomfort to
around 2–27% of the general population, with an increase with age
(Gallagher & O'mahony, 2009).
Although the exact aetiology of constipation remains unknown,
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Suares et al. (2011), amongst others, has identified that low levels of
physical activity, medication, depression and dietary composition are
all likely to contribute to the incidence of constipation. Specifically,
consuming less than the recommended daily fibre intake of 25 g/day
has been associated with an increased incidence of constipation (Suares
& Ford, 2011). In a recent meta-analysis, increased dietary fibre has
been shown to be a useful treatment in those people suffering with
constipation (Rao, Yu, & Fedewa, 2015), although how to increase
dietary fibre intake remains an area of concern, and it is not known if all
types of fibres have equal effects.
Inulin is a soluble dietary fibre that occurs as a storage poly-
saccharide in a variety of plants (Schaafsma & Slavin, 2015). A specific
subset of dietary fibres, such as inulin, can selectively stimulate certain
gut microbiota species and those fibres may be termed prebiotics. The
most recent prebiotic definition of the International Scientific Asso-
ciation of Pro- and Prebiotics (ISAPP) is “a substrate that is selectively
utilised by the host microorganisms conferring a health benefit” (Gibson
et al., 2017). Inulin, derived from the chicory root, is well established
for its prebiotic properties, as recognised by ISAPP. Inulin fibre passes
through the upper GIT undigested, reaching the colon where it is fer-
mented by bacteria thereby modulating the bacteria residing in the GIT,
i.e. ‘gut microbiota’ (Gibson & Roberfroid, 1995). Inulin has been
shown to improve bowel habit through increased stool weight, softer
stools, reduced GIT symptoms, and improved quality of life (Castiglia-
Delavaud et al., 1998; Den Hond, Geypens, & Ghoos, 2000; Vandeputte
et al., 2017a). Although the exact mechanism of how inulin may im-
prove GIT health and relieve constipation are not completely under-
stood, the impact of nutrition (Flint, Scott, Louis, & Duncan, 2012), and
more recently inulin's ability to modulate the gut microbiota have been
suggested to play a role (Vandeputte et al., 2017a).
The gut microbiota has been shown to contribute towards nutrition,
metabolism, immune response, intestinal architecture, and GIT health
(Hooper & Gordon, 2001). Changes in ‘normal’ bowel habits, commonly
reported in people with constipation, have been linked to changes in
gut microbiota composition, which has been suggested to have a
functional role in the pathogenesis of constipation (Kim et al., 2015;
Zhu et al., 2014). Consumption of foods high in fibre has been shown to
be an effective treatment for symptoms of constipation (Lembo &
Camilleri, 2003; Voderholzer et al., 1997). Fibre provides a substrate
for microbial fermentation, and in so doing stimulates the growth of
intestinal microbiota (Flint et al., 2012). Modulating the gut microbiota
through fibre intake has the potential to increase the abundance of
potentially beneficial bacteria, whilst reducing potentially pathogenic
bacteria (Chen et al., 2013), and this may alleviate the symptoms of
constipation (Ingvar, 2004). Intake of native chicory inulin has pre-
viously been shown to stimulate changes in the relative abundance of
bifidobacteria in several studies using culturing or quantitative PCR
(Schaafsma & Slavin, 2015), and secondly mixes of chicory inulin type
fructans show similar effects using 16S rRNA sequencing approaches
(Reimer et al., 2017). More recently inulin has been shown to increase
Bifidobacterium, Bilophila and Anaerostipes in constipated subjects
(Vandeputte et al., 2017a).
The primary aim of the current study was to investigate the effect of
native chicory inulin on stool frequency in healthy middle-aged and
older adults, albeit with self-reported unsatisfactory bowel movements.
Secondary aims were to assess associated effects on other aspects of GIT
function, specifically stool consistency; quality of life; and gut micro-
biota.
2. Materials and methods
2.1. Subjects
Subjects were recruited for Trial A, in Amsterdam, Netherlands, or
Trial B, in Newcastle upon Tyne, United Kingdom, with circulation of
flyers, visits to general practitioners, and advertisements in regional
and local newspapers. Volunteers received a comprehensive informa-
tion brochure and were assessed for eligibility based on the exclusion
and inclusion criteria by completing a questionnaire, which was con-
firmed at a screening visit by an independent physician, nurse or re-
search technician. At the screening visit, subjects were provided a
complete oral explanation of the purpose and procedures of the trial,
and questions were addressed. After the questionnaire was reviewed to
decide on the inclusion of the subjects, signed written informed consent
was obtained from all subjects before any protocol-specific procedures
were carried out. The studies were reviewed and advised by the Ethics
Committees of the Independent Review Board of Amsterdam and the
Faculty of Science, Agriculture and Engineering of Newcastle
University, respectively. Trials A and B were registered under CCMO as
NL27269.003.09 in Amsterdam and as ISRCTN97558933 in Newcastle,
respectively.
Trial A. The number of subjects recruited for trial A was based on
stool frequency data from a similar cross-over trial (Den Hond et al.,
2000) (Table 1), showing that 22 subjects would provide a power of
90% to detect a difference between groups of 1.5 in weekly stool fre-
quency with alpha 5%. Sixteen volunteers were recruited for the study
and 10 subjects, who met the criteria and submitted all requested re-
cords, completed the study. Both the average and median age was 52
years, ranging from 45 to 62 years.
Trial B. Trial B was powered based on the stool frequency data from
trial A, showing that 17 volunteers completing the study would be
necessary to determine a difference of 1.3 at the 5% significance level
with a power of 90%. With an assumed drop out percentage of 30%, the
anticipated enrolment was 22 volunteers. However, recruitment con-
tinued for slightly longer, in order to increase the number of male vo-
lunteers. Twenty-six volunteers were recruited, 21 female and 5 male,
20 of which completed the study (16 female and 4 male). Both the
average and median age was 62 years, ranging from 51 to 74 years.
Inclusion criteria: Inclusion criteria for both trials were both
healthy men and women aged between 40 and 75 years inclusive with
self-reported low stool frequency, i.e. 2 days or more per week without
successful bowel movements.
Exclusion criteria: Volunteers were excluded from the study if they
had a clinical diagnosis of constipation as defined by the Rome criteria
(Longstreth et al., 2006); had anatomical causes of reduced bowel
function; a history of colonic or anal surgery; or inflammatory bowel
diseases (Crohn's disease, ulcerative colitis). Subjects that had major
surgery or current or recent (< 5 years) diagnosis of cancer, coronary
heart disease or diabetes were also excluded. Other exclusion criteria
included current or recent medication including the use of opium pre-
parations, antibiotics, laxatives or diuretics in the 3 months prior to
study commencement that may influence constipation symptoms and/
or gut microbiota composition, or any other condition that in the view
of the volunteer's general practitioner or the study manager may make
the volunteer unsuitable for the trial (see further details in Supple-
mentary Document 1).
2.2. Study design
Both studies used a randomised and double-blind, cross-over pla-
cebo-controlled trial design. In the first treatment period, half of the
subjects received either inulin or placebo respectively and this was
reversed in the second treatment period (Fig. 1). The duration of each
treatment period was 5 weeks and a wash-out period of at least 2 weeks
followed the first treatment period (Fig. 1).
2.3. Study products, dosing schedule and diet during the trial
The trial used Frutafit® inulin HD as produced by Sensus BV
(Roosendaal, the Netherlands) from chicory roots. Frutafit® inulin has
been confirmed as a safe ingredient through its formal review of Sensus’
GRAS documentation (FDA, 2003). The placebo maltodextrin (MD 20)
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was obtained from Avebe (Foxhol, the Netherlands). Maltodextrin is a
fully digestible carbohydrate, not a fibre. Maltodextrin behaves simi-
larly to inulin in solution and tasting behaviour thus the placebo drink
was identical in taste and texture to the inulin drink. Each volunteer
received all the treatment materials in two batches, one batch at the
start of each treatment period. In Trial A, each subject received 80 pre-
mixed orange juice drinks containing 5 g of either inulin or placebo
(enough for up to 40 days); the subjects were suggested to consume one
drink in the morning and one drink mid-afternoon. In Trial B, each
subject received 80 sachets with each 5 g inulin or placebo and a
package with 80,100ml bottles of shelf-stable juice or water (according
to preference), and a mixing container. The orange juice used for this
trial was selected as it has previously been shown not to have any pre-
biotic effects (Hickey, Calloway, & Murphy, 1972). The subjects were
instructed to mix one sachet and one portion of the liquid in the mixing
container, and drink the mixture within 2 h of mixing, twice a day with
breakfast and mid-afternoon. Volunteers used 1 portion of juice mix per
day in the first three days when starting the study. After 3 days and
during the rest of the trial the volunteers were instructed to consume 2
portions per day to reach the 10 g dose, and to return any unused study
product to the study site (for compliance monitoring).
Throughout the trial, volunteers were asked to follow their normal
diet and exercise habits and to try to avoid changes during the study,
other than to avoid foods containing prebiotics and probiotics, which
included foods containing inulin-type fructans (Examples
Supplementary Document 1). Compliance to the recommended diet was
confirmed verbally at each post randomisation study visit.
2.4. Randomisation and blinding
At the start of the first 5-week treatment period, volunteers were
randomly assigned to either inulin treatment or placebo. In Trial A,
volunteers were randomised into the two groups by the study team. In
Trial B, randomisation was stratified by gender using a computer-gen-
erated semi-sequential multiple-coded approach (Fig. 2), where each of
the 2 treatments were allocated 3 different codes, and the allocation
balanced to near equal proportions for every 6 volunteers.
This provided two specific benefits, compared with a simple random
allocation of each volunteer into one of the two groups: a) If an adverse
event required unblinding of one volunteer, this would not auto-
matically unblind all the other volunteers as well; b) Even with rela-
tively low volunteer numbers in one of the genders, the probability of
substantially different numbers of subjects allocated to the two treat-
ments within a gender was much lower than if simple random alloca-
tion was used (detailed description of the algorithm is in
Supplementary Document 1, the macro is included as an Excel file,
Supplementary Document 2). Study sachets were prepared by Sensus
BV in pre-packed boxes pre-labelled with the subject numbers and study
phase (see ‘Final label’ in Fig. 2). Subjects and all research staff involved
in the conduct of the study were thus verifiably blinded to the treatment
allocation, i.e. the sequence of study product intake, until final database
lock. For safety reasons, sealed envelopes specifying the treatment
corresponding to each of the different treatment labels were kept with
the research team, to allow emergency unblinding if necessary. After
the trial, Sensus BV was able to verify that all seals were intact, except
for the agreed unblinding of the code corresponding to the non-urgent
adverse event mentioned below.
2.5. Subject data collection and questionnaires
During weeks 1, 3 and 5 of each study period, volunteers were re-
quired to fill in bowel habit diaries for both Trials A and B. The bowel
habit daily diary for Trial A included self-assessment of seven para-
meters, whereby each day the subject noted the time of each defecation
event, stool consistency (Bristol stool scale), as well as scores from 1 to
4 (normal, reasonable, high, very high) for intestinal symptoms (ease of
defecation, flatulence, rumbling, bloating and cramps) as previously
described (Alles et al., 2007). In Trial B, the bowel habit daily diary was
modified by removing a question on ‘ease of defecation’. Additionally, a
validated questionnaire Patient Assessment of Constipation - Symptom
(PAC-SYM) (under licence from Mapi Research Trust, France) was
provided to the volunteers to be completed prior to and following the
study period. Although this questionnaire has been developed for pa-
tients with a clinical diagnosis of constipation, it includes a wide range
of symptoms with varying severity, and therefore is relevant for the
healthy volunteers recruited to the present study. The corresponding
Quality of Life questionnaire (PAC-QoL) was not used, since the ranges
used for the outcomes were strongly skewed towards hospitalised pa-
tients, which was not relevant for this study population. Adverse events
and concomitant medication were recorded for the duration of the trials
in accordance with ICH/GCP guidelines. One volunteer experienced a
migraine episode during an inulin consumption period. However, in
consultation with the volunteer's GP it was concluded that the event
was not related to the treatment.
2.6. Bacterial DNA extraction and 16S rRNA gene sequencing bacterial
profiling
Volunteers from Trial B were asked to provide a stool sample prior
to commencing the inulin or placebo treatment and again after 5 weeks
Fig. 1. Trial design for A and B. Numbers 1–5 denote the number of weeks during the treatment phase. (PAQ-sym - Patient Assessment of Constipation Symptoms).
Measures which were only conducted in trial B be are labelled “trial B” (PAQ-sym questionnaire and stool sample).
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supplementation, and after the washout period immediately prior to
starting the second arm of the study; this was repeated upon completing
the cross-over (Fig. 1) (four stool samples in total). Each stool sample
was homogenised at room temperature using a mortar and pestle as
previously described (Vandeputte, Tito, Vanleeuwen, Falony, & Raes,
2017b), and a 5 g aliquot was stored at−80 °C until DNA was extracted
in order to minimise alterations in bacterial composition following 16S
rRNA gene sequencing (Lauber, Zhou, Gordon, Knight, & Fierer, 2010).
The samples were managed according to the requirements of the
Human Tissue Authority (HTA). An aliquot of 300mg of stool from
each time point was extracted using MP FastDNA™ Spin Kit for Feces
following the manufacturer's instructions (Qbiogene, MP Biomedicals,
Illkirch, France). The V4 region of the 16S rRNA gene was amplified
using barcoded Illumina adaptors primer pair 515F/806R and then
sequenced in the MiSeq platform (Illumina) using the 2×250 bp
paired-end protocol yielding pair-end reads that overlap almost com-
pletely. The primers used for amplification contain adapters for MiSeq
sequencing and single-end barcodes allowing pooling and direct se-
quencing of PCR products (Caporaso et al., 2012).
16S rRNA gene pipeline incorporated alignment-based and phylo-
genetic approaches to maximise resolution of data. Paired reads were
demultiplexed based on the unique molecular barcodes and then
merged using the USEARCH v7.0.1090 (Edgar, 2010), allowing no
mismatches with a minimum overlap of 50 bases. The merged reads
were then trimmed at the first base with Q5, followed by a quality filter
was applied and reads containing>0.05 expected errors were re-
moved. The 16S rRNA gene sequences were then clustered into Op-
erational Taxonomic Units (OTU), a term used to classify groups of
bacteria that are closely related at a cut-off similarity value of 97%
using the UPARSE algorithm (Edgar, 2013). The OTUs were mapped
onto an optimised version of the SILVA database that incorporated only
the 16S V4 region to determine taxonomies (Quast et al., 2013). Bac-
terial abundances were recovered by mapping the demultiplexed reads
to the UPARSE OTUs. A custom script was then constructed for a rar-
efied OTU table using output files from the previous two steps, allowing
analysis of phylogenetic trends, alpha-diversity and beta-diversity
(Lozupone & Knight, 2005). Each sample was rarefied to 2997 reads,
(range of 134–141,466). Four samples below this were removed for gut
microbiota analysis. Raw data is publicly available through the short
read archive database.
2.7. Statistical analysis
Data recorded in the bowel habit diaries during weeks 3 and 5 of
each treatment period were transformed into difference data (by sub-
tracting the average of the recorded week 3 and 5 scores during the
placebo period from the average week 3 and 5 scores for the corre-
sponding inulin period) in order to express the effect of the treatment as
two numerical values for each volunteer. The overall trial average
difference for each volunteer was also calculated, using the combined
average of weeks 3 and 5 for the difference in outcome between the two
treatments. These difference data were tested for (normal) distribution
before being analysed for the statistical difference from zero using a one
sample T-test. Additionally, for data that were recorded in a compar-
able way in both Trial A and Trial B (i.e. stool frequency, consistency,
flatulence, bloating, cramping, rumbling), the overall trial average
difference for each volunteer were analysed together, combining all
volunteers in both trials. The values were analysed using ANOVA
(General Linear Model in Minitab). This analysis distinguished between
volunteers who during week 1 of their placebo period met the criterion
of≥ two days without bowel movements per week i.e. ‘low initial stool
frequency’, and those who did not meet this criterion, thereby had less
than two days without bowel movements i.e. ‘high initial stool fre-
quency’. Due to the run-in dosing schedule in week 1 and anticipated
increasing effect with inulin treatment over time, the bowel habit data
recorded during week 1 were not used otherwise. The ‘low initial stool
frequency’ criterion was met by 10 volunteers from Trial A and 6 from
Trial B. The model factors were initial frequency (either low or high),
and site (either Trial A or Trial B), nested within initial frequency, to
determine the mean and standard deviation and significance corre-
sponding to the hypotheses: (1) that the overall effect differs from 0; (2)
whether the outcome differed among volunteers with low or high initial
frequency (interaction with initial frequency); and (3) whether the
outcome was affected by site among volunteers with low initial fre-
quency. Where the outcome showed a significant interaction with the
initial frequency, an additional one-sample T-test was used to analyse
the data from volunteers with low initial frequency only. A Bonferroni
correction was applied to the p-values for the 6 secondary outcomes
(other than the primary outcome of change in stool frequency) resulting
in α=0.008, rather than the 0.05 for the primary outcome, The ana-
lysis and visualisation of bacterial communities was conducted using R
Fig. 2. Illustration of principle of semi-sequential randomisation with offset. (Text in brackets explains how it was done), other text explains the purpose of the
corresponding step.
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(R-Core-Team., 2014). The phyloseq package was used to import data
and calculate alpha and beta diversity metrics (Mcmurdie & Holmes,
2013). The Kruskal-Wallis test was used when comparing three or more
categories. A Wilcoxon signed rank test was used to assess between-
group differences for changes in relative abundance of bacteria at pre
and post intervention. Correlations between two continuous variables
was analysed using linear regression models, using p-values to indicate
the probability that the slope of the regression is zero. Differences in
beta diversity (weighted and unweighted Unifrac and Bray Curtis were
assessed using PERMANOVA. All p-values presented were adjusted for
multiple comparisons using the FDR algorithm (Benjamini & Hochberg,
1995). The effect size and significance of each covariate were de-
termined using the ‘envfit’ function in ‘vegan’ comparing the difference
in the centroids of volunteer, gender, inulin and time-point relative to
the total variation (Oksanen et al., 2015). All p-values derived from
envfit were adjusted for multiple comparisons using FDR adjustment.
Ordination was performed using NMDS based on Bray–Curtis dissim-
ilarity. The significance value was determined based on 10,000 per-
mutations. Data obtained from the PAC-SYM questionnaire (Trial B
only) were added up into domain scores (abdominal, stool, rectal,
overall) and changes in scores between weeks 1 and 5 were calculated.
As data were not numeric, a non-parametric Wilcoxon signed rank test
was then conducted to compare the change from baseline scores be-
tween treatments.
3. Results
3.1. Trial A: Bowel habit analysis
The results of the bowel habit analysis for Trial A are presented in
Fig. 3 and Supplementary Table 1. There was a significant increase in
stool frequency at week 5 (p=0.04) and for the average trial score
(p=0.01). These changes correspond to an increase in frequency of 1.3
bowel movements per week; thus bowel movements increased from an
average ± standard error of mean (SEM) of 3.6 ± 0.25 to 4.9 ± 0.23
per week (Fig. 3a). No change in stool consistency was observed. There
was a non-significant trend for an increase in bloating when weeks 3
and 5 were averaged p=0.08), for flatulence at week 5 (p=0.07) and
averaged (p=0.06), and for abdominal cramping for the average trial
score (p=0.06). Data tables can be found in Supplementary Table 1.
3.2. Trial B: Bowel habit analysis
In Trial B there was no effect on stool frequency outcome when
calculated as average of all volunteers (Fig. 4 and Supplementary
Table 2). However, it was observed that the recorded number of stools
per day was substantially higher than the inclusion criteria specified
(i.e. two days or more per week without successful bowel movements).
Across all weeks and treatments, including the first week of the placebo
treatment, the average number was slightly above one bowel movement
per day. In the first week of the placebo treatment, only six subjects (of
the 20 that fully completed the bowel habit diary) had two or more days
without any bowel movements per week on average in line with the
inclusion criterion. It is noteworthy that the average difference scores
during both weeks 3 and 5 for these six low-frequency subjects showed
a non-significant increase in frequency of 0.28 per week from 5.1 to 5.4
bowel movements per week. The average frequency among subjects
with high initial frequency was slightly reduced, by 0.89 per week, from
9.4 to 8.5 bowel movements per week, and this was also non-significant
(p=0.36)
The recorded values for both primary and secondary outcomes are
shown in Supplementary Table 2. There were no overall changes in the
stool frequency, and for the secondary outcomes, when the alpha level
is corrected for multiple comparisons (Bonferroni, α=0.008), none of
the results reached statistical significance within the trial.
3.3. Response of initial low stool frequency subjects to inulin (both trials)
Interactions between inulin versus placebo treatment with low or
high initial stool frequency in subjects from Trials A and B were ana-
lysed for those outcomes in the bowel habit diaries or questionnaires
where identical scales were used. The number of volunteers included in
the combination of trials was 30. Histograms produced in the Minitab
output were visually analysed and visible outliers were removed from
the analysis. Analyses reported in this section are data with outliers
omitted and the number of volunteers included in each analysis along
with analysis outcomes can be found in Table 1.
When the trial data for stool frequency for all subjects in Trial A and
B were combined, stool frequency was not significantly different be-
tween inulin and placebo treatments. However, there was an interac-
tion with initial frequency of defecation (p=0.025), and the low fre-
quency subjects showed an increase in stool frequency of 0.7 per week
compared to placebo. In addition, there was an increase in stool type
implying softer stool consistency of 0.28 points on the Bristol stool
chart when data of both trials were combined, irrespective of initial
stool frequency (p=0.008). When the alpha level for this secondary
outcome was corrected for multiple comparisons (Bonferroni,
α=0.008), this was significantly different. There was a non-significant
increase in cramping in subjects with a low initial frequency from both
Trials A and B (p=0.08). There were no other significant differences
for subjects in Trial B with either low or high initial stool frequency
(data not shown).
3.4. Assessment of constipation symptoms in trial B
The outcome from the PAC-SYM questionnaire showed that no
significant differences were found between inulin or placebo con-
sumption for changes from the start to the end of each treatment period
of any of the symptoms of discomfort tested using this validated
questionnaire (Table 2). Global (overall) symptoms were reduced by a
median of 2.5 points compared to the placebo (i.e.−4.5 compared with
−2), however, all symptoms improved during the 5-week period irre-
spective of the treatment (all change values were negative except
rectal); this suggests a strong placebo effect. Still, the reduction of
global symptoms by a median value of 4.5 points in the subjects on
inulin treatment strongly indicates a lack of significant side effects due
to inulin.
3.5. Impact of inulin on faecal microbiota in trial B
Following a rarefaction curve analysis 4 samples were removed
from the Inulin period (2 pre and 2 post). For these volunteers all re-
maining samples were removed from Inulin and Placebo arms periods
of the study, giving a final sample size of 20 for Inulin and Placebo.
Compositional analysis showed that Bacteroidetes and Firmicutes were
the dominant phyla at baseline in the stool microbiota and following
both arms of the intervention, with no significant differences
(p > 0.05) between the inulin and placebo at pre or post each arm of
the intervention. Volunteers had a mean of 33% and 32% for
Bacteroidetes, and 55% and 56% for Firmicutes prior to consuming the
placebo or inulin, respectively (Fig. 5). At genus level in both the pla-
cebo and inulin periods of the study, the dominant bacteria were Bac-
teroides, Alistipes, Faecalibacterium and Subdoligranulum (Fig. 6). Fol-
lowing the 5 week intervention there was a marginal increase in
Alistipes (p=0.61) and Bifidobacterium (p=0.33), which were not
present in the placebo arm of the study, and a larger increase in Fae-
calibacterium (p=0.61), following inulin consumption (Fig. 7 and
Supplementary Table 3). Following 5 weeks intervention, there were no
significant changes at phylum or genus level (p > 0.05) in either the
placebo or inulin consumption arm of the study. We also compared the
differences between pre and post inulin and placebo periods in the
change from pre to post (effect size), however, none of the effects were
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significant (all p > 0.05; Supplementary Table 3).
α-Diversity was analysed by comparing the number of OTUs and
Shannon Index prior to and following each individual arm of the study.
α-Diversity analysis demonstrated that there was no significant differ-
ence between diversity of samples collected at baseline and following 5
weeks of the intervention in the placebo arm of the study (p=0.73).
There was a small increase in the number of OTUs following the inulin
intervention (p=0.42), which was mirrored by a small decline in OTUs
following placebo consumption, suggesting inulin supplementation
may be responsible for this increase. (Supplementary Fig. 1 and
Supplementary Table 3). The Shannon diversity index, a measure of
richness and evenness (i.e., how evenly an OTU is distributed
throughout the sample) was not significantly different between pre and
post for the placebo (p=0.53) or inulin (p=0.25) arms of the trial
(Supplementary Table 3). There was no significant difference in the
changes of OTUs and Shannon Index between the inulin and placebo
periods (all P > 0.05; Supplementary Table 3).
To assess β-diversity, weighted and unweighted Unifrac were
Fig. 3. Mean difference scores, standard errors for all bowel habit data from Trial A. For each subject and outcome the difference score is the average value per day in
the inulin period minus the average value per day in the placebo period. Data shown is the average difference score for weeks 3 and 5 and the combined difference
scores for weeks 3 and 5 (average for the study). * denotes T-test outcomes for the values being different from 0.
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Fig. 4. Mean difference scores and standard errors for all bowel habit data from the Trial B. Data shown is the average difference in score for weeks 3 and 5 and the
combined difference scores for weeks 3 and 5 (trial average).
Table 1
Mean difference scores and standard errors for bowel habit data from all subjects in Trials A and B, and subjects with low initial stool frequency (LISF) from Trials A
and B (A & B-LISF). Data shown as ‘Mean’ are the average of difference scores for weeks 3 and 5, with corresponding SEM.
Outcome Data from Trial Number of subjects Mean SEM p-value -interaction LISF versus HISF‡ P-value
Stool frequency A & B 28 0.08 0.05 0.025* 0.98
A & B-LISF only 16 0.91 0.06 0.032*§
Stool consistency A & B 29 0.28 0.10 0.91 0.008*
Flatulence A & B 30 −0.14 0.09 0.39 0.125
Rumbling A & B 30 −0.02 0.05 0.43 0.67
Bloating A & B 29 0.03 0.04 0.125 0.39
Cramping A & B 30 −0.02 0.03 0.088 0.67
*denotes significant difference<0.008 (for secondary outcomes with Bonferroni correction).
† p-values for ‘Trials A & B’ indicate if the difference scores for all subjects together are different from 0.
‡ p-value interaction LISF versus High Initial Stool Frequency (HISF) show if the subjects in both trials with LISF had a significantly different outcome than those in
Trial B subjects with HISF. § p-value for stool frequency, where this interaction is significant for subjects in Trial A & B-LISF, shows the difference between inulin
treatment and placebo was significant for those subjects in both trials who had low initial frequency.
A.W. Watson, et al. Food Hydrocolloids 96 (2019) 688–698
694
conducted and visualised using principle co-ordinate analysis (PCoA).
There was no significant difference in β-diversity between pre and post
placebo demonstrated by the Weighted Unifrac (p=0.95, R-
squared=0.01) and Unweighted Unifrac (p=1.00, R squared=0.01)
(Fig. 7 A and B, respectively). There was also no significant difference
in β-diversity between pre and post following inulin supplementation,
Weighted Unifrac (p=0.85, R squared= 0.02), Unweighted Unifrac
(p=0.99, R squared= 0.01) (Fig. 7 C and D, respectively) and Bray
Curtis (p=0.97, R squared=0.02).
We investigated the impact of initial stool frequency on gut mi-
crobiota composition, as determined using the inclusion criteria; low
frequency: ‘≥ two days without bowel movements per week during
week 1 of the placebo period', and high frequency: ' < two days without
bowel movements'. There were no significant changes in any taxa
abundance or overall gut microbiota composition between low and high
stool frequency volunteers within or between the inulin and placebo
periods prior to or following the five week interventions (p > 0.05).
Combining the sequence data from all volunteers at all time points
we found significant associations between volunteers (p=0.004) and
gender (p=0.006) with microbiota profiles, accounting for 87% and
11% of the overall variability, respectively. Time point and treatment
period were not significantly associated with the microbiota profiles
(p=0.920) and (p=0.922), respectively, explaining only 0.3% and
0.1% of the overall variability, respectively. This corroborates the
previous findings that each volunteer has a unique bacterial commu-
nity, which is stable over time despite inulin intervention.
4. Discussion
These randomised, double blind, placebo-controlled trials assessed
the effects of inulin on bowel symptoms of constipation, with stool
frequency as the primary outcome, quality of life and gut microbiota
composition in middle-aged to elderly populations. The study demon-
strated that 10 g/d of inulin improved stool frequency and consistency
in older adults only with low stool frequency; there were no other
significant changes in gastrointestinal symptoms. There were no sig-
nificant changes in gut microbiota composition.
In order to participate in this study, subjects were screened for low
stool frequency with the criterion for inclusion set at two to four days
per week without successful bowel movement (since they were ex-
cluded if they had clinically relevant constipation, defined according to
the Rome criteria as less than three successful bowel movements per
week (Longstreth et al., 2006). This criterion was challenging to
achieve. In Trial A, there was a significant increase of greater than 1
additional bowel movement per week in stool frequency between the
subjects consuming inulin versus the placebo; all these subjects had low
initial stool frequency. In Trial B, there was no overall effect of the
inulin on stool frequency, however, many subjects in Trial B did not
report a low stool frequency during the trial, notably also not for the
placebo. The recorded number of stools per day for the Trial B subjects
was substantially higher in the first week of the trial, in fact the average
exceeded one bowel movement per day, irrespective of treatment.
There are several possible explanations for this. One is a possible strong
placebo effect from participating in this study (Staudacher, Irving,
Lomer, & Whelan, 2017). In addition, some volunteers had very vari-
able bowel movements during Trial B, with multiple stools on some
days and none on others. This may create an impression to the subject
of frequently being unable to pass stools, even though the total fre-
quency of successful attempts was not particularly low. Prolonged
screening of this parameter for 2–3 weeks prior to commencing the trial
is recommended for future studies, preferably with all volunteers re-
ceiving a placebo product during this stage.
Interestingly, when data of subjects with low initial stool frequency
from Trials A and B were combined, there was a statistically significant
increase in frequency of 0.77 defecations per week. These improve-
ments in defecation frequency are in line with previous reports on
subjects with more serious clinically relevant constipation (Den Hond
et al., 2000; Micka, Siepelmeyer, Holz, Theis, & Schön, 2017; Sobotka
et al., 1997). It appears that the effect of native inulin to improving
Table 2
Median change from baseline score and score range after 5 weeks of treatment
and outcomes of the Wilcoxon Rank Test for all PAC-SYM variables (symptoms).
Symptoms Treatment Median Range P- Value
Abdominal Inulin −0.5 2–−6 0.29
Placebo −1 6–−4
Stool Inulin −3 4–−11 0.54
Placebo −2 4–−10
Rectal Inulin 0 3–−5 0.72
Placebo 0 3–−4
Global Inulin −4.5 4–−22 0.76
Placebo −2 −10–−12
Fig. 5. Boxplots showing the relative abundance of the top eight bacterial phyla prior to and following 5 weeks consuming inulin or placebo. No significant
differences were identified.
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stool frequency can be effectively observed in persons with low stool
frequency without a clinical diagnosis of constipation.
In contrast, for the 12 subjects with high initial stool frequency,
inulin consumption appeared to result in a (non-significant) reduction
(−0.89 ± 0.75) in the frequency of defecation. This may be explained
if volunteers pass fewer larger stools rather than several smaller ones,
an outcome which has been previously shown upon inulin consumption
(Castiglia-Delavaud et al., 1998; Causey, Feirtag, Gallaher, Tungland, &
Slavin, 2000). In future studies this may be monitored using measure-
ments of faecal output to assess if stool size is increased following inulin
consumption. Irrespective of the reasons for the high initial frequency
in some volunteers, we report that following inulin consumption stool
frequency was marginally increased. These data suggest that volunteers
with variable stool frequency may benefit from inulin in terms of
improving regularity. However the present study was not designed or
powered to test for such an effect.
The role of the gut microbiota in patients with poor bowel move-
ments has received considerable interest over the last decade, which
has predominantly been possible due to technological advances.
Irrespective of the exact aetiology, altered intestinal transit is associated
with altered bacterial composition and gut microbiota dysbiosis (VAN
Felius et al., 2003). Inulin has been shown to improve bowel move-
ments, GI symptoms, quality of life and increase faecal output in var-
ious adult populations (Castiglia-Delavaud et al., 1998; Den Hond et al.,
2000; Marteau et al., 2011; Vandeputte et al., 2017a). These im-
provements have generally been associated with modest changes in gut
microbiota composition, specifically Bifidobacteria, but also with Bilo-
phila, Anaerostipes and Clostridium in constipated subjects amongst
Fig. 6. Boxplots showing the relative abundance of the top ten bacterial phyla prior to and following 5 weeks consuming inulin or placebo. No significant differences
were identified.
Fig. 7. Principle component analysis of Weighted and Unweighted Unifrac analysis for pre and post Placebo (A and B, respectively) and Inulin (C and D, respec-
tively).
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others (Dewulf et al., 2013; Kim, Lee, & Meyer, 2007; Linetzky
Waitzberg et al., 2012; Vandeputte et al., 2017a). These changes are
likely due to the ability of inulin to reach the colon where it is fer-
mented by bacteria, producing short chain fatty acids, which are re-
cognised as health promoting metabolites (Kau, Ahern, Griffin,
Goodman, & Gordon, 2011).
In the current study we observed an increase in stool frequency in
volunteers with low stool frequency, as previously reported
(Vandeputte et al., 2017a). This could ultimately affect the delivery of
nutrients to the gut microbiota, influence luminal pH and environ-
mental conditions. In contrast to previous studies (Schaafsma & Slavin,
2015; Vandeputte et al., 2017a), we did not report any significant
changes in specific bacterial taxa, notably Bifidobacterium, or changes in
alpha or beta diversity. This outcome may be due to the small number
of subjects, population selected, geographical location, inclusion/ex-
clusion criteria and/or other aspects of the study design. There is evi-
dence in animal studies to show that the response to inulin may be
dependent upon the gut microbiota composition at study commence-
ment (Rodriguez et al., 2018). Here we reported non-significant in-
creases in Faecalibacterium, Bifidobacterium and Alistipes, all of which are
associated with gut health, including increased bacterial diversity, re-
duced triglycerides (Zhernakova et al., 2016), metabolic control and
short chain fatty acid production (Varela et al., 2013; Xu et al., 2015).
In contrast to previously published studies (Dewulf et al., 2013; Kim
et al., 2007; Linetzky Waitzberg et al., 2012; Vandeputte et al., 2017a)
we did not report any significant changes in gut microbiota composi-
tion, despite the improvements in stool frequency. The present study
may not have been sufficiently powered to detect these differences, in
particular considering the effect of the initial gut microbiota composi-
tion as previously suggested (De Preter et al., 2008; Bouhnik et al.,
2004). For example De Preter et al. (2008) reported that the relative
increase in Bifidobacteria were dependent on the initial concentrations
of Bifidobacteria following inulin consumption in healthy volunteers.
However from the perspective of contributing data to future meta-
analyses on this subject, it is noticeable that the directions of the ob-
served trends generally correspond well with the significant effects in
other studies. This is also the reason why the non-significant trends for
other outcomes are reported in the present paper.
The only significant secondary outcome of the trial was the impact
of 10 g of native inulin per day on stool consistency in the subjects.
Results from Trial A and Trial B separately showed no statistically
significant change in stool consistency. However, when data from both
trial sites were combined, stool consistency increased by 0.29 points on
the Bristol stool chart (p=0.008, after correction for multiple out-
comes) a finding also reported after consuming 12 g of Orafti® inulin per
day for 4 weeks (Micka et al., 2017).
We conclude that 10 g native chicory inulin improved stool fre-
quency and stool consistency in otherwise healthy middle-aged adults
with unsatisfactory low stool frequency. Inulin consumption did not
modulate taxa abundance or overall gut microbiota composition sig-
nificantly, however the directions of observed trends were consistent
with published data on other types of inulin. Importantly there were no
indications of potentially negative effects on gastrointestinal symptoms
in these subjects.
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